CL2013002185A1 - Compuestos derivados de terpenos modificados en c-17 y c3, inhibidores de la maduración del vih; compuestos intermediarios; composición farmacéutica que los comprende; su uso para tratar la infección por vih. - Google Patents

Compuestos derivados de terpenos modificados en c-17 y c3, inhibidores de la maduración del vih; compuestos intermediarios; composición farmacéutica que los comprende; su uso para tratar la infección por vih.

Info

Publication number
CL2013002185A1
CL2013002185A1 CL2013002185A CL2013002185A CL2013002185A1 CL 2013002185 A1 CL2013002185 A1 CL 2013002185A1 CL 2013002185 A CL2013002185 A CL 2013002185A CL 2013002185 A CL2013002185 A CL 2013002185A CL 2013002185 A1 CL2013002185 A1 CL 2013002185A1
Authority
CL
Chile
Prior art keywords
compounds
inhibitors
pharmaceutical composition
hiv
intermediary
Prior art date
Application number
CL2013002185A
Other languages
English (en)
Spanish (es)
Inventor
Yan Chen
Alicia Regueiro-Ren
Zheng Liu
Ny Sin
Brian Lee Venables
Sing-Yuen Sit
Jie Chen
Nicholas A Meanwell
Jacob Swidorski
Original Assignee
Viiv Healthcare Uk No 4 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Uk No 4 Ltd filed Critical Viiv Healthcare Uk No 4 Ltd
Publication of CL2013002185A1 publication Critical patent/CL2013002185A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J63/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J63/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2013002185A 2011-01-31 2013-07-30 Compuestos derivados de terpenos modificados en c-17 y c3, inhibidores de la maduración del vih; compuestos intermediarios; composición farmacéutica que los comprende; su uso para tratar la infección por vih. CL2013002185A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161437893P 2011-01-31 2011-01-31

Publications (1)

Publication Number Publication Date
CL2013002185A1 true CL2013002185A1 (es) 2013-12-27

Family

ID=45567147

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013002185A CL2013002185A1 (es) 2011-01-31 2013-07-30 Compuestos derivados de terpenos modificados en c-17 y c3, inhibidores de la maduración del vih; compuestos intermediarios; composición farmacéutica que los comprende; su uso para tratar la infección por vih.

Country Status (25)

Country Link
US (3) US8846647B2 (enExample)
EP (1) EP2670765B1 (enExample)
JP (1) JP6001560B2 (enExample)
KR (1) KR101886467B1 (enExample)
CN (1) CN103429607B (enExample)
AR (1) AR085053A1 (enExample)
AU (1) AU2012212509B2 (enExample)
BR (1) BR112013019419A2 (enExample)
CA (1) CA2826113C (enExample)
CL (1) CL2013002185A1 (enExample)
CO (1) CO6751275A2 (enExample)
EA (1) EA022470B1 (enExample)
ES (1) ES2653847T3 (enExample)
IL (1) IL227678B (enExample)
MA (1) MA34909B1 (enExample)
MY (1) MY162186A (enExample)
PE (1) PE20141152A1 (enExample)
PH (1) PH12013501528A1 (enExample)
PT (1) PT2670765T (enExample)
SG (1) SG192144A1 (enExample)
TN (1) TN2013000321A1 (enExample)
TW (1) TWI628188B (enExample)
UY (1) UY33886A (enExample)
WO (1) WO2012106190A1 (enExample)
ZA (1) ZA201306546B (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2703274T3 (es) 2008-04-18 2019-03-07 Reata Pharmaceuticals Inc Moduladores de la inflamación antioxidantes: derivados del ácido oleanólico con modificaciones amino y otras en C-17
EA020467B1 (ru) 2008-04-18 2014-11-28 Ритэ Фамэсутикл, Инк. Соединения, обладающие противовоспалительной активностью, и фармацевтическая композиция на их основе
KR101782020B1 (ko) 2008-04-18 2017-09-26 리타 파마슈티컬스 잉크. 산화방지성 염증 조절제 c-17 일치된 올레아놀산 유도체
EA022588B1 (ru) 2008-04-18 2016-01-29 Ритэ Фамэсутикл, Инк. Антиоксидантные модуляторы воспаления: производные олеанолевой кислоты с насыщением в с-кольце
EA025568B1 (ru) 2010-12-17 2017-01-30 Рита Фармасьютикалз, Инк. Пиразолильные и пиримидинильные трициклические еноны в качестве антиоксидантных модуляторов воспаления
DK2670764T3 (en) * 2011-01-31 2015-12-07 Bristol Myers Squibb Co C-28 AMINES OF MODIFIED C-3-BETULIN ACID DERIVATIVES AS ANTI-HUMIDITY INHIBITORS
TR201909788T4 (tr) 2011-03-11 2019-07-22 Reata Pharmaceuticals Inc C4-monometil triterpenoid türevleri ve bunların kullanım yöntemleri.
TW201317255A (zh) 2011-09-21 2013-05-01 必治妥美雅史谷比公司 具抗病毒活性之新穎樺木酸衍生物
US8906889B2 (en) * 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
PL3444261T3 (pl) 2012-04-27 2021-07-19 Reata Pharmaceuticals, Inc. Pochodne 2,2-difluoropropionamidowe bardoksolonu metylu, ich kompozycje farmaceutyczne i formy polimorficzne do zastosowania w leczeniu określonych stanów
US8889854B2 (en) 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
US9556222B2 (en) 2012-06-15 2017-01-31 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
JP6389174B2 (ja) * 2012-08-15 2018-09-12 グラクソ グループ リミテッドGlaxo Group Limited 化学的方法
WO2014040073A1 (en) 2012-09-10 2014-03-13 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
ME03522B (me) 2012-09-10 2020-04-20 Reata Pharmaceuticals Inc C-17 alkandiil i alkendiil derivati oleanolne kisjeline i metode za njihovu upotrebu
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
KR20150115881A (ko) * 2013-02-06 2015-10-14 브리스톨-마이어스 스큅 컴퍼니 Hiv 성숙 억제 활성을 갖는 c-19 변형된 트리테르페노이드
AU2014218754B2 (en) * 2013-02-25 2017-04-20 VIIV Healthcare UK (No.5) Limited C-3 alkyl and alkenyl modified betulinic acid derivatives useful in the treatment of HIV
HRP20201645T1 (hr) 2014-04-11 2020-12-25 VIIV Healthcare UK(No.4) Limited Triterpenoidi s aktivnošću inhibiranja zrenja hiv, supstituirani na položaju 3 nearomatskim prstenom koji nosi halogenalkilni supstituent
US9920090B2 (en) 2014-06-19 2018-03-20 VIIV Healthcare UK (No.5) Limited Betulinic acid derivatives with HIV maturation inhibitory activity
WO2016077561A1 (en) 2014-11-14 2016-05-19 Bristol-Myers Squibb Company Oxolupene derivatives
EP3218388A1 (en) * 2014-11-14 2017-09-20 VIIV Healthcare UK (No.5) Limited C17-aryl substituted betulinic acid analogs
KR20170135970A (ko) 2015-04-14 2017-12-08 비브 헬스케어 유케이 (넘버4) 리미티드 Hiv 성숙화 억제제를 생산하는 방법
CN108026140A (zh) 2015-07-28 2018-05-11 葛兰素史克知识产权第二有限公司 用于预防或治疗hiv感染的白桦脂醇衍生物
RU2018105352A (ru) 2015-07-28 2019-08-29 ГлаксоСмитКлайн Интеллекчуал Проперти (N2) Лимитед Производные бетулина для предупреждения или лечения ВИЧ-инфекций
WO2017025901A1 (en) * 2015-08-11 2017-02-16 Hetero Research Foundation Novel c28-analogues with c3-modifications of triterpene derivatives as hiv inhibitors
BR112018005861B1 (pt) 2015-09-23 2022-11-22 Reata Pharmaceuticals, Inc Compostos derivados de ácido oleanólico modificado com c4 para a inibição de il-17, composição farmacêutica e usos terapêuticos dos ditos compostos
EP3353158A1 (en) 2015-09-24 2018-08-01 Glaxosmithkline Intellectual Property (No. 2) Limited Compounds with hiv maturation inhibitory activity
US20200268772A1 (en) 2015-11-20 2020-08-27 ViiV Healthcare UK (No.4) Limited Hiv maturation inhibitor formulations
BR112018014622A2 (pt) * 2016-01-20 2018-12-11 Glaxosmithkline Ip No 2 Ltd ?composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para tratar uma infecção por hiv e para prevenir uma infecção por hiv, e, uso de um composto ou sal?
AR107512A1 (es) 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
EP3478703A1 (en) * 2016-06-30 2019-05-08 ViiV Healthcare UK (No.5) Limited Triterpenoid inhibitors of human immunodeficiency virus replication
WO2018044822A1 (en) * 2016-08-31 2018-03-08 Viiv Healthcare Company Combinations and uses and treatments thereof
IL318937A (en) 2017-08-04 2025-04-01 Ardelyx Inc History of glycyrrhetinic acid for the treatment of hyperkalemia
JP6926939B2 (ja) * 2017-10-23 2021-08-25 東京エレクトロン株式会社 半導体装置の製造方法
JP6977474B2 (ja) * 2017-10-23 2021-12-08 東京エレクトロン株式会社 半導体装置の製造方法
PT3784349T (pt) 2018-04-24 2024-01-22 Viiv Healthcare Uk No 5 Ltd Compostos com atividade inibidora de maturação do hiv
PL237998B1 (pl) 2018-05-28 2021-06-28 Narodowy Inst Lekow Fosfonowe pochodne kwasu 3-karboksyacylobetulinowego, sposób ich otrzymywania oraz ich zastosowanie
WO2019246461A1 (en) 2018-06-20 2019-12-26 Reata Pharmaceuticals, Inc. Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith
EP4234016B1 (en) 2019-02-07 2025-06-18 Ardelyx, Inc. Glycyrrhetinic acid derivatives for use in treating hyperkalemia
PL3924361T3 (pl) 2019-02-11 2024-03-18 Hetero Labs Limited Nowe pochodne triterpenu jako inhibitory wirusa hiv
US12344631B2 (en) 2019-07-19 2025-07-01 Reata Pharmaceuticals, Inc. C17 polar-substituted heteroaromatic synthetic triterpenoids and methods of use thereof
GB2598300A (en) * 2020-08-21 2022-03-02 Univ Durham Cross-linking method and applications in bioconjugation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5869535A (en) 1995-03-21 1999-02-09 The Board Of Trustees Of The University Of Illinois Method and composition for selectively inhibiting melanoma
US5962527A (en) 1995-03-21 1999-10-05 The Board Of Trustees Of The University Of Illinois Method and composition for treating cancers
US5679828A (en) 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
WO2004089357A2 (en) 2003-04-02 2004-10-21 Regents Of The University Of Minnesota Anti-fungal formulation of triterpene and essential oil
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
CA2560266A1 (en) 2004-03-17 2005-09-29 Panacos Pharmaceuticals, Inc. Pharmaceutical salts of 3-o-(3',3'-dimethylsuccinyl) betulinic acid
TW200628161A (en) 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
US8067620B2 (en) 2005-05-04 2011-11-29 Medicines For Malaria Venture Mmv Dispiro 1,2,4-trioxolane antimalarials
WO2008127364A2 (en) * 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
WO2008115281A2 (en) 2006-10-16 2008-09-25 Myriad Genetics, Inc. Compounds for treating viral infections
EP2257567A1 (en) 2008-02-14 2010-12-08 Virochem Pharma Inc. Novel 17 beta lupane derivatives
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
CA2801487C (en) * 2010-06-04 2017-12-05 Bristol-Myers Squibb Company Modified c-3 betulinic acid derivatives as hiv maturation inhibitors
DK2576586T3 (en) * 2010-06-04 2015-11-23 Bristol Myers Squibb Co C-28 AMINES OF MODIFIED C-3-BETULIN ACID DERIVATIVES AS ANTI-HUMIDITY INHIBITORS

Also Published As

Publication number Publication date
NZ614871A (en) 2014-06-27
CN103429607B (zh) 2016-02-17
EA022470B1 (ru) 2016-01-29
KR101886467B1 (ko) 2018-08-07
EP2670765B1 (en) 2017-10-18
CN103429607A (zh) 2013-12-04
PH12013501528A1 (en) 2013-09-16
IL227678A0 (en) 2013-09-30
US20140343000A1 (en) 2014-11-20
AU2012212509A1 (en) 2013-09-19
MA34909B1 (fr) 2014-02-01
CO6751275A2 (es) 2013-09-16
AU2012212509B2 (en) 2016-01-21
IL227678B (en) 2018-04-30
EA201391127A1 (ru) 2013-12-30
ES2653847T3 (es) 2018-02-09
US20130035318A1 (en) 2013-02-07
AR085053A1 (es) 2013-08-07
SG192144A1 (en) 2013-08-30
TW201309717A (zh) 2013-03-01
TWI628188B (zh) 2018-07-01
KR20140016279A (ko) 2014-02-07
MY162186A (en) 2017-05-31
CA2826113C (en) 2018-09-04
PE20141152A1 (es) 2014-09-22
EP2670765A1 (en) 2013-12-11
US20160151387A1 (en) 2016-06-02
WO2012106190A1 (en) 2012-08-09
ZA201306546B (en) 2015-03-25
PT2670765T (pt) 2018-01-08
CA2826113A1 (en) 2012-08-09
UY33886A (es) 2012-07-31
JP2014503595A (ja) 2014-02-13
TN2013000321A1 (en) 2015-01-20
BR112013019419A2 (pt) 2019-12-03
US8846647B2 (en) 2014-09-30
JP6001560B2 (ja) 2016-10-05

Similar Documents

Publication Publication Date Title
CL2013002185A1 (es) Compuestos derivados de terpenos modificados en c-17 y c3, inhibidores de la maduración del vih; compuestos intermediarios; composición farmacéutica que los comprende; su uso para tratar la infección por vih.
CL2019002204A1 (es) Compuestos inhibidores del vih.
GT201500088A (es) Derivados de 5-fenoxi-3h-pirimidin-4-ona y su uso como inhibidores de la transcriptasa inversa del vih
UY33480A (es) Compuestos terapeuticos, composicion farmaceutica que lo comprende, metodo de tratamiento y su uso para la manufactura de un medicamento.
CL2015001864A1 (es) Compuestos derivados de espiropirido[1,2-a]pirazina sustituidos, como inhibidores de la integrasa del vih; composicion farmaceutica que los comprende; y su uso para la profilaxis o el tratamiento de una infeccion por vih.
DOP2017000151A (es) Derivados de quinazolina utilizados para tratar el vih
PE20151067A1 (es) Inhibidores de autotaxina
DOP2016000208A (es) Benzimidazol-2-aminas como inhibidores de midh1
CR20130560A (es) Compuestos de bezotiazol y su uso farmacéutico
CL2016001120A1 (es) Compuestos derivados de pirrolo1,2-f1,2,4triazina ,composición farmacéutica que los comprende y su uso en el tratamiento de una infección por virus sincicial compuestos intermediarios. pct
MX2017012558A (es) Derivados de ácido biliar como agonistas de fxr/tgr5 y métodos para su uso.
GT201300254A (es) Triazolopiridinas
DOP2014000008A (es) 4-imidazopiridazina-1-il-benzamidas y 4-imidazotriazina-1-il-benzamidas como inhibidores de btk
CR20160337A (es) Nuevas heteroarildihidropirimidinas 6-fusionadas para el tratamiento y la profilaxis de la infección por virus de la hepatitis b
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
BR112017013440A2 (pt) compostos de isoquinolina para o tratamento de hiv
CO7170160A2 (es) Nuevas 6-aminoacido-heteroarildihidropirimidinas para el tratamiento y profilaxis de la infección del virus de la hepatitis b
DOP2014000133A (es) Triazolopiridinas sustituidas
MX2013012053A (es) Inhibidores de replicacion viral, su proceso de preparacion y sus usos terapeuticos.
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
DOP2012000256A (es) Inhibidores no nucleosídicos de la transcriptasa inversa
UY37378A (es) Compuestos tricíclicos fusionados de piridazinona útiles para tratar infecciones de orthomyxovirus
CL2018001210A1 (es) Compuestos de criptoficina novedosos y productos conjugados, su preparación y su uso terapéutico.
EA201591406A1 (ru) C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич